Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Clinical Features and Treatment Outcomes of Grey Zone Lymphoma (GZL), Unclassifiable B-Cell Lymphoma with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma - a Real-Life Multicenter Study By the Croatian Cooperative Group for Hematologic Diseases (KroHem)

Ida Hude, Klara Brčić, Martina Morić Perić, Vibor Milunović, Milan Vujčić, Ivan Krecak, Zdravko Mitrović, Božena Coha, Slavko Gašparov, Snježana Dotlić, Ivana Ilić, Sandra Bašić-Kinda, Igor Aurer, Goran Rinčić

Blood (2023) 142 (Supplement 1): 7394.

https://doi.org/10.1182/blood-2023-187158

Published: 2023

Journal Articles

Serologic Responses Following Sars-Cov-2 Vaccination and Factors Influencing It in Patients with Hematological Malignant and Non-Malignant Diseases - a Prospective Multicentric Study

Zrinka Sertić, Marko Lucijanic, Sandra Bašić-Kinda, Ranka Serventi Seiwerth, Vlatka Periša, Dubravka Sertić, Bozena Coha, Drazen Pulanic, Dragana Šegulja, Dunja Rogić, Toni Valkovic, Igor Aurer, Nadira Durakovic

Blood (2021) 138 (Supplement 1): 47.

https://doi.org/10.1182/blood-2021-153573

Published: 2021

Journal Articles

Purine Analogues Increase the Risk of Lethal and/or Prolonged COVID19 While Obinutuzumab Increases the Risk of Prolonged but Not Lethal Infection in Patients Treated for Lymphoid Malignancies -a Study of Krohem, the Croatian Group for Hematologic Diseases

Igor Aurer, Ozren Jaksic, Sandra Bašić-Kinda, Stefan Mrdenovic, Slobodanka Ostojic Kolonic, Dominik Lozic, Hrvoje Holik, Sabina Novakovic Coha, Petra Bernes, Ivan Krecak, Martina Moric Peric, Marino Narancic, Zdravko Mitrovic, Toni Valkovic

Blood (2021) 138 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2021-149613

Published: 2021

Journal Articles

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera ® ) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

Jeff Sharman, MD, Anna Marina Liberati, MD, Rodrigo Santucci Silva, MD, Igor Aurer, MD PhD, Jeffery Robbins, MS, Julie Ann Rosenberg, MD, Tahira Khan, MD MS, Ann Alcasid

Blood (2018) 132 (Supplement 1): 394.

https://doi.org/10.1182/blood-2018-99-111248

Published: 2018

Journal Articles

Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma

Sara Alonso, MD, Martina Manni, PhD, Clementine Sarkozy, MD, Marielle Wondergem, MD, Attilio Guarini, MD, Laura Magnano, MD, Miguel Alcoceba, PhD, Martine E.D. Chamuleau, MD, Sara Galimberti, Maria Gomes da Silva, MD, Harald Holte, MD PhD, Emanuele Zucca, MD, Silvia Montoto, MD, Sandra Lockmer, MD, Igor Aurer, MD PhD, Luigi Marcheselli, MSc, Dolores Caballero, MD, Gilles Salles, MD PhD, Massimo Federico, MD

Blood (2018) 132 (Supplement 1): 4145.

https://doi.org/10.1182/blood-2018-99-115956

Published: 2018

Journal Articles

External Validation and Revision of Thrombosis Lymphoma /Throly/ Score

Darko Antic, PhD, Natasa Milic, Biljana Mihaljevic, Bruce Cheson, MD, Mayur Narkhede, MD, Hikmat Abdel-Razeq, Irina Panovska, Sanja Trajkova, Marija Popova, Igor Aurer, Ana Boban, Michele Ghielmini, Alden Moccia, Aurelien Delluc, Jean-Christophe Ianotto, Ulrich Jaeger, MD, Cathrin Skrabs, Grigorios T. Gerotziafas, Jawed Fareed, PhD

Blood (2018) 132 (Supplement 1): 140.

https://doi.org/10.1182/blood-2018-99-115568

Published: 2018

Journal Articles

PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup

Blood (2017) 130 (Supplement 1): 736.

https://doi.org/10.1182/blood.V130.Suppl_1.736.736

Published: 2017

Journal Articles

Extracellular Circulating DNA in Lymphoma Patients: Biological Correlates and Prognostic Impact

Dino Dujmovic, MD, Vedrana Skaro, Sandra Basic-Kinda, MD, Dora Markulin, Ivana Samarzija, Pavle Roncevic, MD, Ivo Radman, MD, Danijela Kolenc, MD PhD, Klara Dubravcic, Gordan Lauc, Igor Aurer, MD PhD

Blood (2014) 124 (21): 5365.

https://doi.org/10.1182/blood.V124.21.5365.5365

Published: 2014

Journal Articles

Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study

Blood (2014) 124 (21): 5979.

https://doi.org/10.1182/blood.V124.21.5979.5979

Published: 2014

Journal Articles

Dose-Intense BACOP for Treatment of High Risk Peripheral T-Cell NHL (PTCL)

Igor Aurer, MD, PhD, Dino Dujmovic, MD, Ivo Radman, MD, Sandra Basic-Kinda, MD, Damir Nemet, MD, PhD, Ivana Ilic, MD, PhD, Ranka Stern-Padovan, MD, PhD, Fedor Santek, MD, PhD, Dubravka Sertic, MD

Blood (2010) 116 (21): 4889.

https://doi.org/10.1182/blood.V116.21.4889.4889

Published: 2010

Journal Articles

Continuous High-Dose Chlorambucil in Previously Untreated Patients with Chronic Lymphocytic Leukemia –Single-Center Experience.

Sandra Basic-Kinda, Igor Aurer, Dino Dujmovic, Ivo Radman, Dubravka Sertic, Klara Dubravcic, Koraljka Gjadrov-Kuvezdic, Drago Batinic, Mirna Sucic, Boris Labar

Blood (2009) 114 (22): 2372.

https://doi.org/10.1182/blood.V114.22.2372.2372

Published: 2009

Journal Articles

Gem-(R)CHOP Versus (R)CHOP: A Randomized Phase II Study of Gemcitabine Combined with (R)CHOP in Untreated Aggressive Non- Hodgkin’s Lymphoma - EORTC Lymphoma Group Protocol 20021

Igor Aurer, Houchingue Eghbali, John M. Raemaekers, Hussein M Khaled, Martine Van Glabbeke, Liliana Baila, Richard van der Maazen

Blood (2008) 112 (11): 3609.

https://doi.org/10.1182/blood.V112.11.3609.3609

Published: 2008

NARROW

Clinical Features and Treatment Outcomes of Grey Zone Lymphoma (GZL), Unclassifiable B-Cell Lymphoma with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma - a Real-Life Multicenter Study By the Croatian Cooperative Group for Hematologic Diseases (KroHem)

Serologic Responses Following Sars-Cov-2 Vaccination and Factors Influencing It in Patients with Hematological Malignant and Non-Malignant Diseases - a Prospective Multicentric Study

Purine Analogues Increase the Risk of Lethal and/or Prolonged COVID19 While Obinutuzumab Increases the Risk of Prolonged but Not Lethal Infection in Patients Treated for Lymphoid Malignancies -a Study of Krohem, the Croatian Group for Hematologic Diseases

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera ® ) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma

External Validation and Revision of Thrombosis Lymphoma /Throly/ Score

PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup

Extracellular Circulating DNA in Lymphoma Patients: Biological Correlates and Prognostic Impact

Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study

Dose-Intense BACOP for Treatment of High Risk Peripheral T-Cell NHL (PTCL)

Continuous High-Dose Chlorambucil in Previously Untreated Patients with Chronic Lymphocytic Leukemia –Single-Center Experience.

Gem-(R)CHOP Versus (R)CHOP: A Randomized Phase II Study of Gemcitabine Combined with (R)CHOP in Untreated Aggressive Non- Hodgkin’s Lymphoma - EORTC Lymphoma Group Protocol 20021

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only